Akeega

niraparib;abiraterone acetate ·
AUTHORISED IN THE EU

What Akeega is used for

Treatment of adult patients with prostate cancer.

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Akeega
Active substance
niraparib;abiraterone acetate
Disease area
Prostatic Neoplasms, Castration-Resistant
Medicine group
Antineoplastic agents
ATC code
L01
Authorised in the EU since
2023

Official information

In the USA

Same active substance: Akeega

In India

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Akeega used for?

Treatment of adult patients with prostate cancer.

What is the active substance in Akeega?

Akeega contains niraparib;abiraterone acetate.

Who makes Akeega?

The EU marketing authorisation holder is .

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.